Table 1.
Baseline characteristics of included trials
| Characteristics | No (%) | Interquartile range | Range |
| Eligible studies: | |||
| Total No of trials | 48 | — | — |
| Median trial size | 131 | 65-246 | 18-18 144 |
| Median follow-up (weeks) | 34 | 24-52 | 24-312 |
| No of studies funded by pharmaceutical companies | 26 (54.2) | — | — |
| No of studies that were phase 2/3 | 12 (25.0) | — | — |
| No of studies that were not phase 2/3 | 36 (75.0) | — | — |
| Participants: | |||
| Mean age (years) | 62.6 | 57.7-64.0 | 45.9-84.1 |
| Male sex (%) | 71.9 | 51.9-75.3 | 27.6-89.7 |
| Mean LDL-C (mg/dL) at baseline | 112.1 | 109.92-150.47 | 82.05-318.40 |
| Mean proportion (%) of patients receiving statin at baseline | 39.6 | 0-100 | 0-100 |
| Region: | |||
| World | 12 (25.0) | — | — |
| Europe* | 9 (18.8) | — | — |
| Asia† | 20 (41.7) | — | — |
| America | 7 (14.6) | — | — |
| Prevention type: | |||
| Primary prevention | 12 (25.0) | — | — |
| Secondary prevention | 24 (50.0) | — | — |
| Unspecific prevention | 12 (25.0) | — | — |
LDL-C=low density lipoprotain cholesterol (1 mg/dL=0.0259 mmol/L).
*One study conducted in Russia was included in this category.
†One study conducted in Turkey was included in this category.